Skip to Content
Search Menu

The Missing Link of Light Chain Smoldering Multiple Myeloma

The iStopMM study provides valuable new data on precursors of multiple myeloma, proposing a novel definition for light chain smoldering myeloma and identifying key risk factors for MCAS.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Fredrik Schjesvold: Bridging Science and Clinical Innovation                                                               

/ Jan Andreasen
Myeloma

Advancing Myeloma Research and Treatment: An Interview with Fredrik Schjesvold

/ Fredrik Schjesvold / Jan Andreasen
Myeloma
Muhammad Kashif

Novel Risk Stratification Method for Bone Disease in Multiple Myeloma Patients Minimizes Radiation Exposure and Lowers Economic Burden

/ Muhammad Kashif
AIASH24Myeloma Play the Video 03:57
Meletios-Athanasios Dimopoulos

Daratumumab Monotherapy Shows Clinical Benefit for Early Intervention for Patients with High-Risk Smoldering Multiple Myeloma

/ Meletios A. Dimopoulos
ASH24Myeloma Play the Video 03:38
Frida Bugge Askeland

Positive Outcome of Steroid Replacement in Transplant-Ineligible Myeloma

/ Frida Bugge Askeland
ASH24Myeloma Play the Video 03:10
Fredrik Schjesvold

ASH 2024 Highlights: Early Smouldering Myeloma Treatment and Breakthrough Therapies in Multiple Myeloma Take Center Stage

/ Fredrik Schjesvold
ASH24Myeloma Play the Video 02:57
Alex Lesokhin

Elranatamab Demonstrates Sustained Efficacy with Reduced Dosing Frequency in Refractory Multiple Myeloma

/ Alexander Lesokhin
ASH24Myeloma Play the Video 4:45

The Aquila Study Strongly Supports the Benefit of Early Intervention with Daratumumab Monotherapy in Patients with High-Risk Smoldering Multiple Myeloma

/ Jan Andreasen
ASH24Myeloma
Fredrik Schjesvold

The Trispecific Antibody SAR’257 Discontinued After Phase 1 Findings

/ Fredrik Schjesvold
ASH24Myeloma Play the Video 03:29
Back to top